Effects of magnolol and honokiol blend on performance,egg quality,hepatic lipid metabolism,and intestinal morphology of hens at late laying cycle

Magnolol and its isomer honokiol are polyphenols with anti-oxidative and anti-inflammatory activities. We evaluated the effects of magnolol and honokiol supplementation alone or in combination with hen diets during the late laying cycle. A total of 540 Jingfen pink-shell laying hens (50 weeks old) were randomly assigned to six treatments: a control diet and diets supplemented with 300 mg/kg magnolol (M₃₀₀), honokiol (H₃₀₀), or 300 mg/kg total phenols with a magnolol/honokiol ratio of 2:1 (M₂₀₀H₁₀₀), 1:2 (M₁₀₀H₂₀₀), and 1:1 (M₁₅₀H₁₅₀). Compared with that of the control, all supplementation groups had higher laying rates and the M₃₀₀, M₁₀₀H₂₀₀, and M₁₅₀H₁₅₀ groups showed comparatively lower feed conversion ratios. Magnolol and honokiol supplementation increased the Haugh units of fresh eggs at week 62 and alleviated the decline of the Haugh units of eggs stored for 14 days. Compared with that of the control group, the serum total antioxidant capacity of the M₁₀₀H₂₀₀ and M₁₅₀H₁₅₀ groups significantly increased, and all supplementation groups had higher total antioxidant capacity and lower malondialdehyde content in the liver. With respect to lipid metabolism, the M₂₀₀H₁₀₀ and M₁₅₀H₁₅₀ groups had lower total and relative liver weights compared with those of the control and H₃₀₀ groups. The mRNA expression levels of CCAAT enhancer binding protein alpha, sterol regulatory element binding protein-1, fatty acid synthase and stearyl coenzyme A desaturase 1 involved in lipogenesis; microsomal triglyceride transfer protein and apolipoprotein B involved in fatty acid transport; and the proinflammatory cytokine interleukin-1 beta were lower in all supplementation groups compared with those in the control. With respect to gut health, the heights of the jejunum and ileum villi significantly increased in all supplementation groups compared with those of the control, and the jejunum villus heights of the M₃₀₀ and M₁₅₀H₁₅₀ groups were higher than those of the H₃₀₀ and M₁₀₀H₂₀₀ groups. The H₃₀₀ and M₁₅₀H₁₅₀ groups had higher mRNA expression levels of zonula occludens-1 in the ileum compared with those in the control and M₃₀₀ groups, whereas all supplementation groups had higher mRNA levels of claudin-1 than that of the control group. In conclusion, magnolol and honokiol improved hen performance and the albumen quality of fresh and stored eggs by improving the antioxidant capacity, liver lipid metabolism, and intestinal health of laying hens. The combination of magnolol and honokiol at a 1:1 ratio may be an optimal choice for hen diet supplementation.     

Chronic metformin intake and gastric cancer: A pooled analysis within the Stomach cancer Pooling (StoP) Project

IntroductionThe association between chronic use of metformin and risk of gastric cancer (GC) has been investigated with contradicting results. We aimed to study the association between chronic use of metformin and GC by using data from the Stomach cancer Pooling (StoP) Project, an epidemiological consortium of case-control studies on GC.MethodsData from three studies of the StoP Project with available information on metformin intake were analyzed.Multivariable logistic regression models were used to estimate study-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between chronic use of metformin and GC risk. Analyses were adjusted for sex, age, socioeconomic status, body mass index, smoking status, alcohol drinking status, and history of diabetes. Study-specific ORs and 95% CIs were then pooled with a random-effects model.The dose-response relationship between the duration of metformin intake and GC was assessed with a one-stage logistic model, and the duration of intake was modelled using second-order fractional polynomials.ResultsThe OR of GC in metformin users versus non-users was 1.01 (95% CI=0.61, 1.67). The association between metformin and GC did not change among different strata of study participants’ characteristics or when restricting the analyses to those with a history of diabetes.The dose-response analysis showed a slightly reducing trend in the OR of GC and a borderline significant association with increasing duration of metformin intake.ConclusionsThe results of our study do not clearly support an association between chronic use of metformin and GC, warranting further research.     

Molecular mechanism of therapeutic approaches for human gastric cancer stem cells

Gastric cancer(GC)is a primary cause of cancer-related mortality worldwide,and even after therapeutic gastrectomy,survival rates remain poor.The presence of gastric cancer stem cells(GCSCs)is thought to be the major reason for resistance to anticancer treatment(chemotherapy or radiotherapy),and for the development of tumor recurrence,epithelial–mesenchymal transition,and metastases.Additionally,GCSCs have the capacity for self-renewal,differentiation,and tumor initiation.They also synthesize antiapoptotic factors,demonstrate higher performance of drug efflux pumps,and display cell plasticity abilities.Moreover,the tumor microenvironment(TME;tumor niche)that surrounds GCSCs contains secreted growth factors and supports angiogenesis and is thus responsible for the maintenance of the growing tumor.However,the genesis of GCSCs is unclear and exploration of the source of GCSCs is essential.In this review,we provide up-todate information about GCSC-surface/intracellular markers and GCSC-mediated pathways and their role in tumor development.This information will support improved diagnosis,novel therapeutic approaches,and better prognosis using GCSC-targeting agents as a potentially effective treatment choice following surgical resection or in combination with chemotherapy and radiotherapy.To date,most anti-GCSC blockers when used alone have been reported as unsatisfactory anticancer agents.However,when used in combination with adjuvant therapy,treatment can improve.By providing insights into the molecular mechanisms of GCSCs associated with tumors in GC,the aim is to optimize anti-GCSCs molecular approaches for GC therapy in combination with chemotherapy,radiotherapy,or other adjuvant treatment.     

G蛋白偶联胆汁酸受体1促进胃癌细胞的增殖、迁移和侵袭的实验研究

目的:探讨G蛋白偶联胆汁酸受体1(G-protein coupled bile acid receptor 1,GPBAR1/TGR5)对胃癌细胞增殖、迁移和侵袭的影响。方法:免疫组织化学染色方法(Immunohistochemistry,IHC)检测胃癌及癌旁组织芯片中TGR5表达情况;qRT-PCR及Western blot检测胃癌细胞系中TGR5表达水平;小干扰RNA处理AGS、MKN-45胃癌细胞后构建TGR5敲减细胞系,慢病毒载体转染胃癌SGC-7901细胞构建TGR5过表达细胞系;CCK-8实验、平板克隆形成实验、裸鼠皮下移植瘤实验检测TGR5对细胞增殖的影响;流式细胞仪检测TGR5对细胞周期及凋亡的影响;Tanswell实验检测TGR5对胃癌细胞迁移及侵袭的影响;Western blot检测上皮间充质转化(Epithelial-mesenchymal transition,EMT)相关分子β-连环蛋白(β-catenin)、锌脂蛋白转录因子(Snail)、E盒结合锌指蛋白(Zinc finger E-box binding homeobox 1,ZEB)1在AGS、MKN-45及SGC-7901胃癌细胞中的表达。结果:TGR5在胃癌及癌旁组织中均有表达,胃癌组织TGR5高表达率(41.0%)显著高于癌旁组织(9.5%),伴肠化生癌旁组织TGR5高表达率(50%)显著高于不伴肠化生的癌旁组织(0%),胃癌组织TGR5表达与肿瘤大小相关。TGR5在正常人胃上皮永生化细胞株GES-1及各胃癌细胞系中均有表达。TGR5表达敲低的AGS和MKN-45细胞增殖能力减弱、凋亡率显著升高、侵袭和迁移能力显著降低。过表达TGR5的SGC-7901细胞增殖能力增强、克隆形成能力提高、凋亡率明显减低、侵袭和迁移能力显著升高。此外,TGR5过表达显著上调了间质细胞标志物β-catenin、Snail、ZEB1的表达水平。结论:TGR5能够增强胃癌细胞增殖及迁移能力,并抑制细胞凋亡。TGR5可能通过EMT途径介导胃癌细胞转移。     

康力欣胶囊联合FOLFOX4方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响

目的:观察康力欣胶囊联合奥沙利铂、亚叶酸钙、5-氟尿嘧啶(FOLFOX4)方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响。方法:前瞻性选取2018年7月~2021年1月期间来我院接受治疗的胃癌患者80例,根据抽签分为对照组和观察组两组,各为40例。对照组接受FOLFOX4方案治疗,观察组接受康力欣胶囊联合FOLFOX4方案治疗,以3周为1个疗程,治疗2个疗程。观察两组治疗2个疗程后的疗效、生活质量以及治疗期间不良反应状况,对比两组治疗前、治疗2个疗程后的肿瘤标志物和免疫功能指标变化情况。结果:观察组治疗2个疗程后的总有效率高于对照组(P<0.05)。治疗2个疗程后,观察组的肿瘤相关物质群(TSGF)、糖类抗原-199(CA-199)、癌胚抗原(CEA)低于对照组(P<0.05)。治疗2个疗程后,观察组的CD3;、CD4;、自然杀伤细胞(NK)、CD4;/CD8;高于对照组,CD8;低于对照组(P<0.05)。治疗2个疗程后,观察组的生活质量总改善率、卡氏评分(KPS)评分高于对照组(P<0.05)。两组不良反应发生率组间对比无统计学差异(P>0.05)。结论:中晚期胃癌患者采用康力欣胶囊联合FOLFOX4方案治疗,在阻止疾病进展、改善生活质量、提高免疫功能方面均效果确切,优于单纯化疗效果。     

胃康胶囊联合兰索拉唑肠溶胶囊对胃溃疡患者胃肠激素、炎症反应和T淋巴细胞亚群的影响

摘要 目的：观察胃康胶囊联合兰索拉唑肠溶胶囊治疗胃溃疡的疗效及对胃肠激素、炎症反应和T淋巴细胞亚群的影响。方法：选择2018年9月~2021年5月在中国人民解放军31694部队医院消化内科接受治疗的80例胃溃疡患者作为观察对象,根据信封抽签法分为对照组和观察组,各为40例。对照组患者接受兰索拉唑肠溶胶囊治疗,观察组患者接受胃康胶囊联合兰索拉唑肠溶胶囊治疗,连续治疗6周。对比两组临床疗效、幽门螺杆菌（Hp）根除率和溃疡愈合率,观察治疗期间不良反应发生情况,对比两组治疗前、治疗6周后的胃肠激素、血清炎症因子和T淋巴细胞亚群指标水平的变化。结果：观察组的临床总有效率较对照组高（P<0.05）。观察组的Hp根除率和溃疡愈合率均高于对照组（P<0.05）。治疗6周后,两组CD3⁺、CD4⁺、CD4⁺/CD8⁺较治疗前升高,CD8⁺ 较治疗前下降,且观察组的改善效果优于对照组（P<0.05）。治疗6周后,两组胃动素（MTL）水平较治疗前升高,胃泌素（GAS）水平较治疗前下降,且观察组的改善效果优于对照组（P<0.05）。治疗6周后,两组高迁移率族蛋白B1（HMGB1）、白介素-6（IL-6）、C反应蛋白（CRP）水平较治疗前下降,且观察组的改善效果优于对照组（P<0.05）。两组不良反应发生率对比无统计学差异（P>0.05）。结论：兰索拉唑肠溶胶囊联合胃康胶囊可提高胃溃疡患者的溃疡愈合率和Hp根除率,其作用机制可能与调节胃肠激素、炎症反应和T淋巴细胞亚群指标水平有关。     

胃炎性纤维性息肉的临床特征及内镜下诊治

摘要 目的：研究胃炎性纤维性息肉（IFP）的临床特征及内镜下诊断和治疗情况。方法：收集2010.1.1~2021.1.1陕西省人民医院确诊的11例IFP,重点分析其超声内镜表现及临床特征,探索其内镜下治疗价值。结果：IFP多发生在胃窦,均发生于40岁以上人群,男女比例无明显差别,平均直径1.2 cm,大部分临床无症状,有时可引起出血或腹痛。超声内镜示其为粘膜下隆起,孤立、界清,表面多光滑,均起源于粘膜下层,呈低回声,界清,类圆形;内镜下粘膜挖除术治疗IFP,手术时间短,恢复快,并获得完整的标本,术后病理有助确诊。结论：胃炎性纤维性息肉多发生40岁以上人群,多为胃窦孤立的粘膜下病变,多无症状,超声内镜有助于IFP的术前精确评估,内镜下粘膜挖除术是治疗IFP一项安全有效的方法,术后病理最终确诊。     

Reglα蛋白表达在胃癌及癌前病变组织中的变化

目的：观察再生基因1α（Regeneration gene 1α,Regla）在胃癌前病变组织及胃癌组织中的表达变化,探讨Reglot在胃粘膜癌变中发挥的作用,为临床诊治提供理论基础。方法：收集2011年1月-2012年12月在我院接受胃镜活检的患者胃粘膜组织,病理确诊为浅表性胃炎的为正常组,中度以上萎缩及肠化的为癌前病变组及胃腺癌即胃癌组。采用荧光定量PCR的方法检测三组胃粘膜组织中Regla的mRNA表达情况。结果：Reglet的mRNA表达在正常组、癌变组及胃癌组织中呈进行性升高;胃癌组中,低分化及印戒细胞癌和Ⅳ期胃癌患者的Reg1α表达升高最为明显;Regla在不同分化程度的胃癌组织间表达无显著差异;Regla在Ⅳ期胃癌中的表达显著高于I／II期;差异均具有统计学意义（P〈0．05）。结论：作为一种生长因子Regla可能参与了胃粘膜癌变的过程,并且Reglet的高表达可能与胃癌的预后相关。     

外周血树突状细胞CD83＋表达对胃癌术后病人预后影响及意义

目的：探讨胃癌外周血中树突状细胞CD83＋表达对预后的影响及意义。方法：选取2010年1月至2011年6月间我科收治的胃癌病人74例进行分析,均为原位癌或仅有局部淋巴结转移,以外周血树突状细胞CD83＋为研究对象,以术后生存时间为标准,对病人手术预后进行分析。结果：所选74例病人术后3周测得外周血树突状细胞CD83＋表达频数平均值（7．32＋1．88脚,以表达频数中位数7．32％为标准将74例病人分为高频组和低频组两组,每组37人。术后总体生存时间108周-413周,平均生存时间（207＋227）周,其中高值组平均生存时间（247＋121）周,低值组平均生存时间（118＋54）周,两组生存时间具有明显差别（P〈O．05）。结论：胃癌外周血中树突状细胞CD83＋的表达对接受手术病人预后有重要影响,可以作为判断病人预后的参考依据,对预后不良者加以对症及时干预以降低死亡率。     

进展期胃癌的脾门淋巴结转移相关因素的研究

目的:探讨进展期胃癌脾门淋巴结(10组)转移的相关临床病理因素.方法:回顾分析了(2008-2011年)75例胃癌根治术伴10组淋巴结切除的进展期胃癌病例.分析了临床病理学因素和10组淋巴结转移的相关性.结果:本研究结果提示10组淋巴结转移的阳性率为52％.胃下部癌的转移率(20％)相对较低(P=0.000),大弯侧肿瘤的转移率高达76.2％.病灶的侵润深度及病理TNM分期与10组淋巴结阳性率密切相关,组织学类型或分化程度与10组淋巴结转移无统计学相关.病灶小于3 cm病例的10组淋巴结转移的阳性率为0％,而大于9 cm或Borrmann-Ⅳ的肿瘤患者的10组淋巴结转移的阳性率为100％.结论:10组淋巴结转移的高危因素包括:1.中上部胃癌;2.肿瘤位于胃大弯侧;3.大于3 cm; 4.侵达胃壁浆膜层.含以上高危因素的进展期胃癌根治手术中,建议常规行术中快速冰冻检查10组淋巴结是否存在转移;含2个以上高危因素的进展期胃癌建议行脾切除术,或如果技术条件具备应行保留脾的10组淋巴结清扫术以便最终获得R0切除.